歡迎光臨源葉生物,登錄 | 注冊(cè) |
當(dāng)前位置: 首頁(yè) > 小分子抑制劑 > GPCR/GProtein > E7046

瀏覽歷史

S83013

E7046

源葉(MedMol) 99%
  • 英文名:
  • E7046
  • 別名:
  • E7046; E-7046; E 7046
  • CAS號(hào):
  • 1369489-71-3
  • 分子式:
  • C22H18F5N3O4
  • 分子量:
  • 483.388036
  • 核磁/質(zhì)譜:
品牌貨號(hào)產(chǎn)品規(guī)格價(jià)格(RMB) 庫(kù)存(上海) 北京 武漢 南京 數(shù)量計(jì)量單位 加入購(gòu)物車...
源葉(MedMol) S83013-5mg 99% ¥250.00元 5 - - - EA 加入購(gòu)物車
源葉(MedMol) S83013-10mg 99% ¥370.00元 6 - - - EA 加入購(gòu)物車
源葉(MedMol) S83013-25mg 99% ¥630.00元 6 - - - EA 加入購(gòu)物車
源葉(MedMol) S83013-100mg 99% ¥1720.00元 預(yù)計(jì)交期:2-3天 - - - EA 加入購(gòu)物車
大包裝詢價(jià)

提交您的電話號(hào)碼并同意《個(gè)人信息授權(quán)與保護(hù)申明》,到貨后將短信提示。
提交

產(chǎn)品介紹

參考文獻(xiàn)

質(zhì)檢證書(COA)

摩爾濃度計(jì)算器

相關(guān)產(chǎn)品

  • 提示:詳情請(qǐng)下載說(shuō)明書。
  • 產(chǎn)品描述: Palupiprant (E7046) is an orally bioavailable and specific EP4 antagonist, with IC50 of 13.5 nM and Ki of 23.14 nM. Palupiprant exhibits anti-tumor activities
  • 靶點(diǎn): IC50: 13.5 nM (EP4) Ki: 23.14 nM (EP4);ProstaglandinReceptor
  • 體外研究:
    Palupiprant (E7046) reverses the immunosuppressive effects of PGE2 on activation and differentiation of human myeloid cells through selective EP4 antagonism。
  • 體內(nèi)研究:
    In the CT-26 tumor model, the E7046/RT combination causes the anti-tumor memory response of 9 animals. In the 4T1 model, the combination of E7046 and RT also produces significant better tumor growth inhibition activity compared with each treatment alone. The combination significantly improves survival by inhibiting the subsequent spontaneous lung metastasis of 4T1 tumors. E7046 (150 mg/kg) inhibits the growth of multiple syngeneic tumor models. Blockade of EP4 signaling promotes anti-tumor DC differentiation and slows tumor growth in mice. E7046 treatment reduces the growth or even rejected established tumors in vivo in a manner dependent on both myeloid and CD8C T cells. Furthermore, co-administration of E7046 and E7777, an IL-2-diphtheria toxin fusion protein that preferentially kills Tregs, synergistically disrupts the myeloid and Treg immunosuppressive networks, resulting in effective and durable anti-tumor immune responses in mouse tumor models.
  • 參考文獻(xiàn):
    1. X. Bao, et al. Combination of a Novel EP4 Antagonist E7046 and Radiation Therapy Promotes Anti-tumor Immune Response and Tumor Rejection in Preclinical Tumor Models. International Journal of Radiation Oncology Biology Physics 2. Diana I. Albu, et al. EP4 Antagonism by E7046 diminishes Myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunity. OncoImmunology.
  • 溶解性: Soluble  in  DMSO
  • 保存條件: -20℃
  • 配置溶液濃度參考:
    1mg 5mg 10mg
    1 mM 2.069 ml 10.344 ml 20.687 ml
    5 mM 0.414 ml 2.069 ml 4.137 ml
    10 mM 0.207 ml 1.034 ml 2.069 ml
    50 mM 0.041 ml 0.207 ml 0.414 ml
  • 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
輸入產(chǎn)品批號(hào):

本計(jì)算器可幫助您計(jì)算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系,公式為:


質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)


  • =
    *
    *


源葉所有產(chǎn)品僅用作科學(xué)研究,銷售產(chǎn)品行為均適用于我司網(wǎng)上所列通用銷售條款。